Non alcoholic Steatohepatitis (Nash) Market Set To Grow To Over $900m In 2017
06 August 2017
Visiongain has launched a new pharma report Nonalcoholic Steatohepatitis (NASH) Market Report to 2027: Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a build up of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Usually, nonalcoholic steatohepatitis (NASH) are silent diseases with few or no symptoms. There may not be any symptoms even if there is any development of cirrhosis due to NASH. The minor symptoms may include discomfort in the upper right side of the abdomen.
The lead Visiongain report analyst for this report commented; “Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. This has led to an increase in the number of incidences and the severity of the disease. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics.
Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases.”
The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. Notable companies in the NASH market include AstraZeneca, Intercept Pharmaceuticals, Inc., GENFIT SA, Gilead Sciences, Inc., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb, Galmed Pharmaceuticals Ltd., Immuron Limited and Novo Nordisk AG amongst others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.